Free Trial
NASDAQ:CODX

Co-Diagnostics (CODX) Stock Price, News & Analysis

Co-Diagnostics logo
$0.35 -0.01 (-2.01%)
As of 04/30/2025 04:00 PM Eastern

About Co-Diagnostics Stock (NASDAQ:CODX)

Key Stats

Today's Range
$0.33
$0.37
50-Day Range
$0.30
$0.61
52-Week Range
$0.28
$2.23
Volume
299,013 shs
Average Volume
192,331 shs
Market Capitalization
$11.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50
Consensus Rating
Buy

Company Overview

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Co-Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

CODX MarketRank™: 

Co-Diagnostics scored higher than 86% of companies evaluated by MarketBeat, and ranked 179th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Co-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Co-Diagnostics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Co-Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Co-Diagnostics are expected to grow in the coming year, from ($1.22) to ($1.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Co-Diagnostics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Co-Diagnostics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Co-Diagnostics has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Co-Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    0.48% of the float of Co-Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Co-Diagnostics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Co-Diagnostics has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Co-Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Co-Diagnostics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.48% of the float of Co-Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Co-Diagnostics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Co-Diagnostics has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Co-Diagnostics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Co-Diagnostics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of Co-Diagnostics is held by insiders.

  • Percentage Held by Institutions

    Only 14.99% of the stock of Co-Diagnostics is held by institutions.

  • Read more about Co-Diagnostics' insider trading history.
Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CODX Stock News Headlines

What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
Co-Diagnostics (NASDAQ:CODX) Coverage Initiated at D. Boral Capital
See More Headlines

CODX Stock Analysis - Frequently Asked Questions

Co-Diagnostics' stock was trading at $0.75 at the start of the year. Since then, CODX shares have decreased by 53.2% and is now trading at $0.3510.
View the best growth stocks for 2025 here
.

Co-Diagnostics, Inc. (NASDAQ:CODX) posted its quarterly earnings results on Thursday, March, 27th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.02. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.38 million. Co-Diagnostics had a negative net margin of 563.93% and a negative trailing twelve-month return on equity of 54.94%.
Read the conference call transcript
.

Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

Last Earnings
3/27/2025
Today
4/30/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CODX
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+1,467.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,330,000.00
Net Margins
-563.93%
Pretax Margin
-510.65%

Debt

Sales & Book Value

Annual Sales
$3.92 million
Price / Cash Flow
N/A
Book Value
$2.81 per share
Price / Book
0.12

Miscellaneous

Free Float
29,982,000
Market Cap
$11.78 million
Optionable
Optionable
Beta
1.21

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:CODX) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners